Q-omics provides the consensus-scored RPS3AP19 profile across patient tissues and cancer cell-line models. RPS3AP19 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPS3AP19 is differentially expressed in 6, with the highest sampling consensus in STAD. Additionally, RPS3AP19 RNA expression shows 9,847 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight ACC, STAD, and ESCA as cancer lineages where RPS3AP19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS3AP19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS3AP19 survival associations across molecular data types. RPS3AP19 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS3AP19 RNA expression–survival associations across cancer types. High RPS3AP19 expression shows unfavorable associations in ACC, KIRP, ESCA, THCA and READ, but favorable associations in HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPS3AP19 RNA expression.
This table summarizes RPS3AP19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPS3AP19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS3AP19 shows lower tumor expression in BRCA, LUSC, UCEC and LUAD and higher tumor expression in STAD and COAD. The STAD box plot shows higher RPS3AP19 RNA expression in tumor versus normal tissue (log2 FC = +0.673, t-test p < 0.001).
This table shows molecular features associated with RPS3AP19 in patient tissues and cancer cell lines. In patient samples, RPS3AP19 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
